Reducing Asthma Disparities by Improving Provider-Patient Communication - Full Text View

Sponsors and Collaborators:	Johns Hopkins University National Institutes of Health (NIH)
Information provided by:	Johns Hopkins University
ClinicalTrials.gov Identifier:	NCT00181194

Purpose

The purpose of this study will be to assess the impact of a culturally-sensitive, patient-focused asthma communication instrument (ACCI) designed to enhance provider-patient communication by prompting and guiding providers in assessments of disease severity and discussion of adherence behaviors with minority patients with asthma.

Condition	Intervention
Asthma	Device: Asthma Control and Communication Instrument

MedlinePlus related topics: Asthma

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Randomized, Single Blind, Placebo Control, Single Group Assignment, Efficacy Study
Official Title:	Reducing Asthma Disparities by Improving Provider-Patient Communication About Asthma Severity and Adherence With Therapy

Further study details as provided by Johns Hopkins University:

Primary Outcome Measures:

Accuracy of Provider Assessment of Asthma Severity
Accuracy of Clinician Assessment of Patient Adherence
Assessment of appropriateness of asthma treatment (consistency of care with asthma guidelines
Patient satisfaction with provider-patient communication and medical care

Secondary Outcome Measures:

These outcomes include indicators of poor asthma control such as health care service use for asthma exacerbations (unscheduled office visits, ER visits, hospitalizations) and use of oral corticosteroid and overuse of inhaled beta-agonist medications.

Estimated Enrollment:	350
Study Start Date:	May 2005
Estimated Study Completion Date:	December 2006

Detailed Description:

Improving communication between health care providers and their patients is the critical first step in efforts designed to reduce asthma-related health disparities in urban areas. Improving communication will help providers tailor asthma therapies to their patients’ needs, and help providers and patients to overcome barriers (e.g., concerns about adverse effects) to adherence with those asthma treatment plans.

Eligibility

Ages Eligible for Study:	12 Years to 85 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

are able to provide informed consent;
report physician-diagnosed asthma;
report asthma symptoms and/or use of short-acting reliever medication at least twice weekly in the past month.

Exclusion Criteria:

state they do not have asthma;
have mild intermittent disease
no recent evidence of disease activity.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00181194

Contacts

Contact: Mayme Grant	410-550-2863	mgrant3@jhmi.edu
Contact: Cecilia Patino, MD	410-550-2618	cpatino2@jhmi.edu

Locations

United States, Maryland
Johns Hopkins Asthma And Allergy Center	Recruiting
Baltimore, Maryland, United States, 21224
Contact: Mayme Grant 410-550-2863 mgrant3@jhmi.edu
Contact: Cecilia Patino, MD 410-550-2618 cpatino2@jhmi.edu
Principal Investigator: Gregory B Diette, MD, MHS

Sponsors and Collaborators

Johns Hopkins University

National Institutes of Health (NIH)

Investigators

Principal Investigator:

Gregory B Diette, MD, MHS

Johns Hopkins Medicine

More Information

Study ID Numbers:	20021855
Study First Received:	September 13, 2005
Last Updated:	September 13, 2005
ClinicalTrials.gov Identifier:	NCT00181194
Health Authority:	United States: Institutional Review Board

Keywords provided by Johns Hopkins University:

Asthma

Study placed in the following topic categories:

Hypersensitivity
Lung Diseases, Obstructive
Respiratory Tract Diseases
Lung Diseases

Hypersensitivity, Immediate
Asthma
Respiratory Hypersensitivity

Additional relevant MeSH terms:

Immune System Diseases
Bronchial Diseases

ClinicalTrials.gov processed this record on January 16, 2009